CRP measurement: Does the assay matter in hemodialysis patients?

Clinical Nephrology

Volumn 70, Issue 6, 2008, Pages 503-507

  Kanaan, Nada ^a   Goffin, E ^a   Maisin, D ^a   Struyven, J ^a   Jadoul, M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Cardiovascular events; CRP level; HD patient mortality

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHRONIC GLOMERULONEPHRITIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEPHROSCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME;

EID: 57349169524     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70503     Document Type: Article

References (12)

1. Clarke JL, Anderson JL, Carlquist JF Roberts RF, Horne BD, Bair TL, Kolek MJ, Mower CP, Crane AM, Roberts WL, Muhlestein JR and Intermountain Heart Collaborative (IHC) Study Group. Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol. 2005; 95: 155-158.
2. den Elzen WP van Manen JG, Boeschoten EW Krediet RT, Dekker FW. The effect of single and repeatedly high concentration of C-reactive protein on cardiovascular and noncardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant. 2006; 21: 1588-1595.
3. Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW and The NECOSAD Study Group. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients - no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant. 2007; Advance Access published July 10, 1-8.
4. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001; 154: 681-689.
5. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-1812.
6. Ridker PM, Cushman M, Stampfer MJ, Tracy RP Hennekens CH. Inflammation, aspirin and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973-979.
7. Tsirpanlis G. The pattern of inflammation and a potential new clinical meaning and usefulness of C-reactive protein in end-stage renal failure patients. Kidney Blood Press Res. 2005; 28: 55-61.
8. Wang AYM, Woo J, Lam CWK, WangM, Sea MMM, Lui SF, LI PKT, Sanderson J. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Sue Nephrol. 2003; 14: 1871-1879.
9. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 2002; 61: S99-S102.
10. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med. 2005; 352: 1611-1613.
11. Yeun JY Levine RA, Mantadilok V Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000; 35: 469-476.
12. Zimmermann J, Herrlinger S, Pruy A, Metzger T Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-658.